BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 16879393)

  • 81. The significance of HER-2/neu/c-erbB-2 gene amplification in benign and malignant breast disease.
    Supanaranond K; Sukarayodhin S; Tanyakaset M; Balachandra K; Jullaksorn D; Rienkijkarn M; Hoisanka N; Tantivanich S
    Southeast Asian J Trop Med Public Health; 1997 Sep; 28(3):631-40. PubMed ID: 9561622
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Her-2/neu oncogene amplification and protein over-expression in interval and screen-detected breast cancers.
    Anttinen J; Kuopio T; Nykanen M; Torkkeli H; Saari U; Juhola M
    Anticancer Res; 2003; 23(5b):4213-8. PubMed ID: 14666627
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Clinical relevance of HER-2/neu expression in germ-cell testicular tumors.
    Mándoky L; Géczi L; Bodrogi I; Tóth J; Csuka O; Kásler M; Bak M
    Anticancer Res; 2004; 24(4):2219-24. PubMed ID: 15330164
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Dual fluorescence in situ hybridization in detection of HER-2 oncogene amplification in primary hepatocellular carcinoma.
    Huang TJ; Huang BJ; Liang QW; Huang CW; Fang Y
    Hepatobiliary Pancreat Dis Int; 2004 Feb; 3(1):62-8. PubMed ID: 14969840
    [TBL] [Abstract][Full Text] [Related]  

  • 85. HER-2/neu oncogene amplification and chromosome 17 aneusomy in endometrial carcinoma: correlation with oncoprotein expression and conventional pathological parameters.
    Cianciulli AM; Guadagni F; Marzano R; Benevolo M; Merola R; Giannarelli D; Marandino F; Vocaturo G; Mariani L; Mottolese M
    J Exp Clin Cancer Res; 2003 Jun; 22(2):265-71. PubMed ID: 12866577
    [TBL] [Abstract][Full Text] [Related]  

  • 86. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma.
    Afify AM; Werness BA; Mark HF
    Exp Mol Pathol; 1999 Jun; 66(2):163-9. PubMed ID: 10409445
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer.
    Schippinger W; Regitnig P; Bauernhofer T; Ploner F; Hofmann G; Krippl P; Wehrschütz M; Lax S; Carney W; Neumann R; Wernecke KD; Samonigg H
    Oncol Rep; 2004 Jun; 11(6):1331-6. PubMed ID: 15138574
    [TBL] [Abstract][Full Text] [Related]  

  • 88. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
    Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Borderline HER-2 breast cancer cases: histochemical versus real-time PCR analysis and impact of different cut-off values.
    Monego G; Arena V; Maggiano N; Costarelli L; Crescenzi A; Zelano G; Amini M; Capelli A; Carbone A
    Scand J Clin Lab Invest; 2007; 67(4):402-12. PubMed ID: 17558895
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Paget's disease of the nipple: a copy number of the genes ERBB2 and CCND1 versus expression of the proteins ERBB-2 and cyclin D1.
    Mrhalova M; Kodet R
    Neoplasma; 2003; 50(6):396-402. PubMed ID: 14689059
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Genetic analysis of HER-2/neu gene amplification in paraffin embedded tumour tissue in women with breast cancer.
    Zadrozny M; Smolarz B; Romanowicz-Makowska H; Kozłowska E; Kulig A
    Pol J Pathol; 2002; 53(4):189-93. PubMed ID: 12597335
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Overexpression/amplification of HER-2/neu is uncommon in invasive carcinoma of the uterine cervix.
    Rosty C; Couturier J; Vincent-Salomon A; Genin P; Fréneaux P; Sigal-Zafrani B; Sastre-Garau X
    Int J Gynecol Pathol; 2004 Jan; 23(1):13-7. PubMed ID: 14668544
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Her-2/neu gene overexpression in breast carcinoma and its association with clinicopathological characteristics of the disease.
    Ahmad A; Bano U; Gondal M; Khan A
    J Coll Physicians Surg Pak; 2009 May; 19(5):297-9. PubMed ID: 19409162
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Comparative analysis of c-erbB-2 (HER-2/neu) in squamous cell carcinoma of the tongue: does over-expression exist? And what is its correlation with traditional diagnostic parameters?
    Angiero F; Sordo RD; Dessy E; Rossi E; Berenzi A; Stefani M; Sidoni A
    J Oral Pathol Med; 2008 Mar; 37(3):145-50. PubMed ID: 18251938
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis.
    Lehr HA; Jacobs TW; Yaziji H; Schnitt SJ; Gown AM
    Am J Clin Pathol; 2001 Jun; 115(6):814-22. PubMed ID: 11392876
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers.
    Marx AH; Burandt EC; Choschzick M; Simon R; Yekebas E; Kaifi JT; Mirlacher M; Atanackovic D; Bokemeyer C; Fiedler W; Terracciano L; Sauter G; Izbicki JR
    Hum Pathol; 2010 Nov; 41(11):1577-85. PubMed ID: 20656317
    [TBL] [Abstract][Full Text] [Related]  

  • 97. p53 and Her-2/neu in juvenile angiofibromas.
    Schick B; Veldung B; Wemmert S; Jung V; Montenarh M; Meese E; Urbschat S
    Oncol Rep; 2005 Mar; 13(3):453-7. PubMed ID: 15706416
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Comparison of multiplex ligation dependent probe amplification to immunohistochemistry for assessing HER-2/neu amplification in invasive breast cancer.
    Purnomosari D; Aryandono T; Setiaji K; Nugraha SB; Pals G; van Diest PJ
    Biotech Histochem; 2006; 81(2-3):79-85. PubMed ID: 16908432
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Amplification and overexpression of HER-2/neu in invasive ductal carcinomas of the pancreas and pancreatic intraepithelial neoplasms and the relationship to the expression of p21(WAF1/CIP1).
    Hermanová M; Lukás Z; Nenutil R; Brázdil J; Kroupová I; Kren L; Pazourková M; Růzicka M; Díte P
    Neoplasma; 2004; 51(2):77-83. PubMed ID: 15190415
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Her-2/neu expression in prostate cancer: a dynamic process?
    Carles J; Lloreta J; Salido M; Font A; Suarez M; Baena V; Nogue M; Domenech M; Fabregat X
    Clin Cancer Res; 2004 Jul; 10(14):4742-5. PubMed ID: 15269147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.